FKBP51/FKBP5 Antibody

Knockdown Validated: FKBP51/FKBP5 Antibody [NB100-68240]

Knockdown Validated: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51/FKBP5 modulates EMT hallmarks. FKBP51/FKBP5 silencing of SAN melanoma cells decreases TGF-b and TbRIII expression. Normalized expression rates (mean +/-S.D.) of TGF-b mRNA levels; (n 1/4). FKBP51/FKBP5 siRNA-treated sample expression 1/4. 1. Western blot assay of TGF-b in SAN melanoma cells treated with nonsilencing (NS) RNA or FKBP51/FKBP5 siRNA. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2013109), licensed under a CC-BY license./4

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] -

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] -

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] -

Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 interacts with the general transcriptional co-activator p300. (a, left) FKBP51 co-immunoprecipitates with p300. (a, right), p300 co-immunoprecipitates with FKBP51. Total-cell lysates were prepared by SAN melanoma cells transfected with FKBP51/Flag. Cell lysates were immunoprecipitated with anti-Kat3B/p300 (IP p300) or anti-Flag (IP FKBP51). Immunoprecipitated & total lysates were then subjected to western blot with anti-FKBP51 or anti-p300. (b) ChIP performed with SAN melanoma cells, silenced (FKBP51 siRNA) or not (NS RNA) for FKBP51. An enrichment of DNA (region at −3450 from TSS of ABCG2 gene) can be observed in p300-immunoprecipitated chromatin (NS RNA) compared with IgG sample. Such an enrichment appeared to be reduced when FKBP51 was silenced (FKBP51 siRNA) Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.